头孢布烯与头孢呋辛随机对照治疗急性细菌性感染临床评价

A randomized controlled clinical study on ceftibuten and cefuroxime in the treatment of bacterial infections

目的进一步评价头孢布烯治疗细菌性感染的安全有效性。方法采用随机对照开放试验方法。头孢布烯组２００ｍｇ，口服；头孢呋辛组７５０ｍｇ，静脉点滴；均为每１２小时一次。疗程７～１４天。结果头孢布烯组及头孢呋辛组分别有６６例及６７例可评价疗效，两组有效率分别为８７．９％及８９．６％。本次观察共分离致病菌１１０株，细菌清除率分别为９０７％及８９３％。两组安全性评价分别为６６例及７０例，不良反应发生率分别为１０．６％与１０．０％。两组经统计学处理差异无显著性（Ｐ＞０．０５）。结论采用头孢布烯治疗急性细菌性感染安全。

Objective Ceftibuten (Cedax) is a third-generation oral cephalosporins with broad spectrum of antibacterial activity. The objective of the study is to evaluate the safety and efficacy of ceftibuten in the treatment of bacterial infections. Methods A randomized controlled clinical study of ceftibuten was conducted and the results were compared with those of cefuroxime. A total of 133 patients was enrolled in the study. 66 patients received ceftibuten 200mg every 12 hours orally and 67 patients received cefuroxime every 12 hours by intravenous infusion could be assessed for clinical efficacy. The duration of treatment was 7～14 days in both groups. Results The overall efficacy rates were 87.9% for the ceftibuten group and 89.6% for the cefuroxime group, whereas the bacterial efficacy rates were 87.0% and 89.3% respectively. 110 strains were isolated from the patients, the bacterial clearance rates were 90.7% and 89.3%, respectively. The adverse drug reaction was evaluated in 66 cases of the ceftibuten group and 70 cases of the cefuroxime group. The adverse drug reaction rates were 10.6% and 10.0%, respectively. There were no statistical differences between these two groups. Conclusion Ceftibuten was effective and safe for the treatment of lower respiratory tract infections and urinary tract infections.